SCOPOLAMINE Drug Patent Profile
✉ Email this page to a colleague
When do Scopolamine patents expire, and when can generic versions of Scopolamine launch?
Scopolamine is a drug marketed by Actavis Labs Ut Inc, Mylan Technologies, Padagis Us, Rhodes Pharms, Riconpharma Llc, and Zydus Pharms. and is included in six NDAs.
The generic ingredient in SCOPOLAMINE is scopolamine. There are twenty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the scopolamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Scopolamine
A generic version of SCOPOLAMINE was approved as scopolamine by PADAGIS US on January 30th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SCOPOLAMINE?
- What are the global sales for SCOPOLAMINE?
- What is Average Wholesale Price for SCOPOLAMINE?
Summary for SCOPOLAMINE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 80 |
| Patent Applications: | 4,067 |
| Drug Prices: | Drug price information for SCOPOLAMINE |
| DailyMed Link: | SCOPOLAMINE at DailyMed |
Recent Clinical Trials for SCOPOLAMINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1 |
| Janssen Scientific Affairs, LLC | Phase 1 |
| Dartmouth-Hitchcock Medical Center | Phase 1 |
Pharmacology for SCOPOLAMINE
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for SCOPOLAMINE
US Patents and Regulatory Information for SCOPOLAMINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Labs Ut Inc | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 208769-001 | Jan 10, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Rhodes Pharms | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 215329-001 | May 6, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Technologies | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 203753-001 | Jun 19, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Padagis Us | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 078830-001 | Jan 30, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Zydus Pharms | SCOPOLAMINE | scopolamine | SYSTEM;TRANSDERMAL | 217893-001 | Aug 29, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
